News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Wealth Awesome Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. BridgeBio Pharma (NasdaqGS:BBIO) reports recent clinical and regulatory milestones across late-stage rare disease assets, including acoramidis, BBP-418, and encaleret. Acoramidis continues to show differentiated …
Enbridge reported a first-quarter adjusted profit of $1.67 billion, exceeding analyst expectations due to strong performance in its gas transmission and utility businesses. The company's secured growth backlog reached C$40 billion, driven by new projects and acquisitions, despite softer results in its liquids pipelines …
This article provides the "Price to sales forward" financial metric for Bridgeline Digital, Inc. (BX:BL43). It is presented within the context of TradingView's platform, offering financial data and tools for market analysis. The content primarily focuses on the specific financial metric for the company …
Oppenheimer Asset Management Inc. has acquired a new position in Enbridge Inc. (NYSE:ENB) during the second quarter, purchasing 597,754 shares valued at approximately $32.4 million. This move contributes to institutional investors now owning 54.6% of the company. Enbridge recently beat quarterly earnings expectations and …
Seabridge Gold announced the results of its special meeting of shareholders, where the spin-out of the Courageous Lake gold project into Valor Gold Corp. was overwhelmingly approved. Shareholders will receive one Valor Share for approximately every 1.957 Seabridge shares held, with Valor expected to …
Wall Street Zen has upgraded Seabridge Gold (NYSE:SA) from "sell" to "hold," though the broader analyst consensus remains "Reduce" with an average price target of $40.00. B. Riley Financial recently initiated coverage with a "buy" rating and a $40 price target. Institutional investors own …
This article from Stock Traders Daily discusses the critical nature of price action for Manhattan Bridge Capital Inc (NASDAQ: LOAN) for tactical trading, based on AI-generated signals. It outlines various institutional trading strategies including position trading, momentum breakout, and risk hedging, and emphasizes multi-timeframe …
Bridgeline Digital reported strong fiscal third-quarter 2026 results, tying a company record with nine new customer wins and expanding relationships with ten existing accounts, driven by accelerating demand for its AI-powered HawkSearch platform. Core product revenue grew 13% on a trailing twelve-month basis, now …
Seabridge Gold reported a significant increase in Q2 2026 net income to $117.5 million, largely due to gains from spinning out the Courageous Lake project. The company is actively advancing its KSM project with major field programs and infrastructure development, supported by a newly …
Sharemaestro market context Price above Trend Line 52 weeks +116.7%This article compares Suncor Energy and Enbridge as dividend stock investments. While Enbridge offers a higher current yield and more stable operations, Suncor is highlighted for its strong balance sheet, potential upside from elevated energy prices, and aggressive share buybacks, making it the preferred …
Enbridge Inc. (ENB) saw its stock rise by 0.16% to C$70.61 on Friday, outperforming the broader Canadian market where the S&P/TSX Composite Index fell by 0.08%. Despite this gain, the company's stock closed 12.4% below its 52-week high of C$80.65, achieved on May 22nd.
One of the more high-flying stocks in the U.S. biotech sector these days is genetic-disease-focused BridgeBio Pharma (NASDAQ: BBIO). That's due almost entirely to the outperformance of its Attruby heart medication. If the generally bullish analyst sentiment on the company is anything to go …
BridgeBio Pharma's (BBIO) transition into a rare disease "commercial powerhouse" is on track and poised to accelerate, RBC Capital Markets said in a Friday note.The company's Attruby drug is gaining traction in first-line treatment settings, while the market for the drug Silver Upgrade to …
Seabridge Gold reported strong financial results for the three and six months ended June 30, 2026, primarily due to a $151.7 million gain from the spin-out of its Courageous Lake Project into Valor Gold Corp. The company achieved a net income of $117.5 million …
This article analyzes what brokers think of BridgeBio Pharma, Inc. (NASDAQ:BBIO) following its second-quarter report. It would likely detail analyst ratings, price targets, and any changes in sentiment post-earnings, providing insights into the company's financial performance and future outlook from an investment perspective.
WaterBridge Infrastructure (NYSE:WBI) just posted record quarterly revenue, raised its full-year outlook for the second straight quarter, and closed a wave of acquisitions that doubled its waste management footprint in the Delaware Basin. Yet the stock fell 1.73% around the release. For a produced …
BridgeBio Pharma, Inc. announced the pricing of an oversubscribed secondary offering of 5,000,000 shares of its common stock by KKR Genetic Disorder L.P. The company itself is not selling shares and will not receive any proceeds from the offering. This transaction aims to further …
BridgeBio Pharma announced the pricing of a secondary offering of 5,000,000 shares of its common stock by existing shareholder KKR Genetic Disorder L.P. BridgeBio will not issue any shares or receive any proceeds from this transaction, which is expected to close on August 17, …
BridgeBio Pharma is facilitating a secondary offering where a KKR-affiliated selling stockholder will sell 5,000,000 shares of common stock at $78.00 per share, totaling $390 million. BridgeBio Pharma will not receive any proceeds from this transaction, as all net proceeds will go to the …
Search by ticker symbol or company name and select a result to open its chart.